Compare Las Vegas Sands Corp. (LVS) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Oscar Health Inc — how do they compare? Las Vegas Sands Corp. trades at $36.17 (market cap $23.38B), while Oscar Health Inc trades at $33.37 (market cap $10.22B). The key difference: Las Vegas Sands Corp. is far larger — about 2.3× Oscar Health Inc's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and Oscar Health Inc for 15 Days on average.
| LVS | OSCR | |
|---|---|---|
Market Cap | $23.38B | $10.22B |
Volume | 6,994,661 | 4,123,394 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $33.81 |
52-Week Low | $35.81 | $10.85 |
Typical Hold Time | 72 Days | 15 Days |
Enterprise Value | $35.27B | $6.57B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $36.10, up 0.81% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Fundamentally, the company shows strong profitability with a 12.59% net margin and consistent revenue growth, reaching $13.02B in 2025. Recent earnings have been mixed, with a Q2 2026 miss after two prior beats. Analyst sentiment remains positive with a 59% buy rating and a $59.78 consensus price target, implying significant upside. The company maintains robust cash flow from operations of $3.02B in 2025.
The outlook for LVS is cautiously optimistic, driven by solid fundamentals and analyst confidence, but weighed by technical weakness and high debt levels. Investment opportunity lies in the substantial discount to price targets, while risks include leverage, Macao regulatory exposure, and volatile earnings. The stock's current valuation multiples, such as a P/E of 13.99, appear attractive if operational execution continues.
OSCR trades at $33.1, up 0.58% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $11.7B in 2025 to a projected $15.3B in 2026, turning to a net profit. Analyst consensus is a $34 price target, with 31% buy ratings. Recent news highlights market share gains and raised 2026 guidance following its Investor Day.
The outlook is positive, driven by execution in the ACA market and new growth avenues, but risks include rising medical costs threatening profitability and a high P/E ratio. The stock offers growth potential if margin expansion continues as guided.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
